MKI67 and breast carcinoma: The stance on Ki67 may also be due to clinical guidelines’ acknowledgement of its predictive value in certain cases10, as well as to the supportive discussion and consensus on its role at the 2021 St Gallen International Breast Cancer Consensus Conference, where there was controversy on the recommended Ki67 threshold to guide decision-making18.